knowledge -WSS

knowledge

author：knowledge 2025-08-23 08:56:57 - browse：28523

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： 3 hurdles to bringing medical devices to the U.S. market

WSS

First U.S. drug developed to treat liver disease MASH is approved

Amid AI frenzy, a top HHS official's quest to create safeguards

How many hemophilia patients actually want gene therapy?

Steward Health Care Massachusetts hospitals face fiscal disaster

As AI in medicine takes off, can 'human in the loop' prevent harm?

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

The science behind Janet Jackson's pregnancy at 49

Sports medicine is finally prioritizing gender equality

WATCH: Why do fingernails fall off when they're damaged?

The high cost of giving birth even with insurance

What would happen to your eyes if you looked at the solar eclipse?

Medical leaders decry Supreme Court decision on affirmative action

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Novavax promises a turnaround & Lilly roils the obesity market

Disclosing genetic information: not as worrisome as once feared

leisure time

Donald Trump's relentless attacks on special counsel Jack Smith

With FDA staff opposed to Sarepta therapy, top official intervened

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Why depression after traumatic brain injury is distinct

WATCH: Why do fingernails fall off when they're damaged?

focus

explore

explore

hotspot